Pyridomycin

Pyridomycin (Erizomycin) is a selective and low cytotoxic inhibitor of Mycobacterium tuberculosis that effectively targets InhA. Pyrdomycin is also an antibiotic that can be obtained from metabolites of Dactylosporangium fulvum. Pyrdomycin can be used in the study of bacterial infections such as tuberculosis[1][2].

Product Specifications

CAS Number

[18791-21-4]

Product Name Alternative

Erizomycin; NSC 246134

UNSPSC

12352005

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/pyridomycin.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=NC=CC=C1O)N[C@H](C(N[C@@H](CC2=CC=CN=C2)[C@@H](O)[C@H]3C)=O)[C@@H](C)OC(/C(OC3=O)=C(C)/CC)=O

Molecular Formula

C27H32N4O8

Molecular Weight

540.56

References & Citations

[1]Hartkoorn RC, et al. Towards a new tuberculosis drug: pyridomycin - nature's isoniazid. EMBO Mol Med. 2012 Oct;4 (10) :1032-42.|[2]Hartkoorn RC, et al. Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA. Nat Chem Biol. 2014 Feb;10 (2) :96-8.